dc.contributor.author |
O'Kennedy, Maretha M
|
|
dc.contributor.author |
Coetzee, P
|
|
dc.contributor.author |
Koekemoer, O
|
|
dc.contributor.author |
Du Plessis, L
|
|
dc.contributor.author |
Lourens, CW
|
|
dc.contributor.author |
Kwezi, Lusisizwe
|
|
dc.contributor.author |
Du Preez, Ilse
|
|
dc.contributor.author |
Mamputha, Sipho
|
|
dc.contributor.author |
Rutkowska, Daria A
|
|
dc.contributor.author |
Lemmer, Yolandy
|
|
dc.date.accessioned |
2022-12-02T07:40:36Z |
|
dc.date.available |
2022-12-02T07:40:36Z |
|
dc.date.issued |
2022-08 |
|
dc.identifier.citation |
O'Kennedy, M.M., Coetzee, P., Koekemoer, O., Du Plessis, L., Lourens, C., Kwezi, L., Du Preez, I. & Mamputha, S. et al. 2022. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. <i>Vaccine, 40(35).</i> http://hdl.handle.net/10204/12545 |
en_ZA |
dc.identifier.issn |
0264-410X |
|
dc.identifier.issn |
1873-2518 |
|
dc.identifier.uri |
https://doi.org/10.1016/j.vaccine.2022.06.079
|
|
dc.identifier.uri |
http://hdl.handle.net/10204/12545
|
|
dc.description.abstract |
Next generation vaccines have the capability to contribute to and revolutionise the veterinary vaccine industry. African horse sickness (AHS) is caused by an arbovirus infection and is characterised by respiratory distress and/or cardiovascular failure and is lethal to horses. Mandatory annual vaccination in endemic areas curtails disease occurrence and severity. However, development of a next generation AHSV vaccine, which is both safe and efficacious, has been an objective globally for years. In this study, both AHSV serotype 5 chimaeric virus-like particles (VLPs) and soluble viral protein 2 (VP2) were successfully produced in Nicotiana benthamiana ΔXT/FT plants, partially purified and validated by gel electrophoresis, transmission electron microscopy and liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing before vaccine formulation. IFNAR-/- mice vaccinated with the adjuvanted VLPs or VP2 antigens in a 10 µg prime-boost regime resulted in high titres of antibodies confirmed by both serum neutralising tests (SNTs) and enzyme-linked immunosorbent assays (ELISA). Although previous studies reported high titres of antibodies in horses when vaccinated with plant-produced AHS homogenous VLPs, this is the first study demonstrating the protective efficacy of both AHSV serotype 5 chimaeric VLPs and soluble AHSV-5 VP2 as vaccine candidates. Complementary to this, coating ELISA plates with the soluble VP2 has the potential to underpin serotype-specific serological assays. |
en_US |
dc.format |
Abstract |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.uri |
https://www.sciencedirect.com/science/article/pii/S0264410X22008489#! |
en_US |
dc.source |
Vaccine, 40(35) |
en_US |
dc.subject |
African horse sickness virus |
en_US |
dc.subject |
AHSV |
en_US |
dc.subject |
Himaeric virus-like particles |
en_US |
dc.subject |
Orbivirus |
en_US |
dc.subject |
Soluble viral protein 2 |
en_US |
dc.subject |
VLPs |
en_US |
dc.subject |
VP2 |
en_US |
dc.title |
Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice |
en_US |
dc.type |
Article |
en_US |
dc.description.pages |
5160-5169 |
en_US |
dc.description.note |
Copyright: 2022 Elsevier Ltd. All rights reserved. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://doi.org/10.1016/j.vaccine.2022.06.079 |
en_US |
dc.description.cluster |
Next Generation Health |
en_US |
dc.description.cluster |
Chemicals |
en_US |
dc.description.impactarea |
Vetnry Mol Diagnostics and Vac |
en_US |
dc.description.impactarea |
BT: Technology Demonstration |
en_US |
dc.description.impactarea |
Human Molecular Diagnostics |
en_US |
dc.identifier.apacitation |
O'Kennedy, M. M., Coetzee, P., Koekemoer, O., Du Plessis, L., Lourens, C., Kwezi, L., ... Lemmer, Y. (2022). Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. <i>Vaccine, 40(35)</i>, http://hdl.handle.net/10204/12545 |
en_ZA |
dc.identifier.chicagocitation |
O'Kennedy, Martha M, P Coetzee, O Koekemoer, L Du Plessis, CW Lourens, Lusisizwe Kwezi, Ilse Du Preez, Sipho Mamputha, Daria A Rutkowska, and Yolandy Lemmer "Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice." <i>Vaccine, 40(35)</i> (2022) http://hdl.handle.net/10204/12545 |
en_ZA |
dc.identifier.vancouvercitation |
O'Kennedy MM, Coetzee P, Koekemoer O, Du Plessis L, Lourens C, Kwezi L, et al. Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice. Vaccine, 40(35). 2022; http://hdl.handle.net/10204/12545. |
en_ZA |
dc.identifier.ris |
TY - Article
AU - O'Kennedy, Martha M
AU - Coetzee, P
AU - Koekemoer, O
AU - Du Plessis, L
AU - Lourens, CW
AU - Kwezi, Lusisizwe
AU - Du Preez, Ilse
AU - Mamputha, Sipho
AU - Rutkowska, Daria A
AU - Lemmer, Yolandy
AB - Next generation vaccines have the capability to contribute to and revolutionise the veterinary vaccine industry. African horse sickness (AHS) is caused by an arbovirus infection and is characterised by respiratory distress and/or cardiovascular failure and is lethal to horses. Mandatory annual vaccination in endemic areas curtails disease occurrence and severity. However, development of a next generation AHSV vaccine, which is both safe and efficacious, has been an objective globally for years. In this study, both AHSV serotype 5 chimaeric virus-like particles (VLPs) and soluble viral protein 2 (VP2) were successfully produced in Nicotiana benthamiana ΔXT/FT plants, partially purified and validated by gel electrophoresis, transmission electron microscopy and liquid chromatography-mass spectrometry (LC-MS/MS) based peptide sequencing before vaccine formulation. IFNAR-/- mice vaccinated with the adjuvanted VLPs or VP2 antigens in a 10 µg prime-boost regime resulted in high titres of antibodies confirmed by both serum neutralising tests (SNTs) and enzyme-linked immunosorbent assays (ELISA). Although previous studies reported high titres of antibodies in horses when vaccinated with plant-produced AHS homogenous VLPs, this is the first study demonstrating the protective efficacy of both AHSV serotype 5 chimaeric VLPs and soluble AHSV-5 VP2 as vaccine candidates. Complementary to this, coating ELISA plates with the soluble VP2 has the potential to underpin serotype-specific serological assays.
DA - 2022-08
DB - ResearchSpace
DP - CSIR
J1 - Vaccine, 40(35)
KW - African horse sickness virus
KW - AHSV
KW - Himaeric virus-like particles
KW - Orbivirus
KW - Soluble viral protein 2
KW - VLPs
KW - VP2
LK - https://researchspace.csir.co.za
PY - 2022
SM - 0264-410X
SM - 1873-2518
T1 - Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice
TI - Protective immunity of plant-produced African horse sickness virus serotype 5 chimaeric virus-like particles (VLPs) and viral protein 2 (VP2) vaccines in IFNAR-/- mice
UR - http://hdl.handle.net/10204/12545
ER - |
en_ZA |
dc.identifier.worklist |
26000 |
en_US |